人肝癌细胞HepaRG

细胞名称

人肝癌细胞HepaRG

货物编码

BFN60808919

产品规格

T25培养瓶x1

1.5ml冻存管x2

细胞数量

1x10^6

1x10^6

保存温度

37℃

-198℃

运输方式

常温保温运输

干冰运输

安全等级

1

用途限制

仅供科研   2类

培养体系

90%DMEM+10%FBS+1%三抗

培养温度

37℃

二氧化碳浓度

5%

简介

人肝癌细胞HepaRG取自女性供体，贴壁培养。

注释

Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-2652.

Characteristics: Can be induced to differentiate into hepatocyte-like cells by exposure to DMSO.

Characteristics: Cell line main applications are sugar and lipid metabolism, physiopathology; drug metabolism and toxicology and viral infection.

Omics: Deep proteome analysis.

Omics: Membrane proteome analysis.

Omics: miRNA expression profiling.

Omics: Transcriptome analysis.

Anecdotal: The 'RG' in the cell name stands for Rumin and Gripon, the two scientists that were influential in the establishment of this cell line.

基因突变

/

HLA信息

/

STR信息

/

参考文献

PubMed=12432097; DOI=10.1073/pnas.232137699

Gripon P., Rumin S., Urban S., Le Seyec J., Glaise D., Cannie I., Guyomard C., Lucas J., Trepo C., Guguen-Guillouzo C.

Infection of a human hepatoma cell line by hepatitis B virus.

Proc. Natl. Acad. Sci. U.S.A. 99:15655-15660(2002)

PubMed=17241619; DOI=10.1016/j.cbi.2006.12.003

Guillouzo A., Corlu A., Aninat C., Glaise D., Morel F., Guguen-Guillouzo C.

The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics.

Chem. Biol. Interact. 168:66-73(2007)

PubMed=17393521; DOI=10.1002/hep.21536

Cerec V., Glaise D., Garnier D., Morosan S., Turlin B., Drenou B., Gripon P., Kremsdorf D., Guguen-Guillouzo C., Corlu A.

Transdifferentiation of hepatocyte-like cells from the human hepatoma HepaRG cell line through bipotent progenitor.

Hepatology 45:957-967(2007)

Patent=US7456018

Gripon P., Guguen-Guillouzo C., Trepo C., Rumin S.

Human hepatoma lines, methods for obtaining same and uses thereof.

Patent number US7456018, 25-Nov-2008

PubMed=20228232; DOI=10.1124/dmd.109.031831

Hart S.N., Li Y., Nakamoto K., Subileau E.-A., Steen D., Zhong X.-B.

A comparison of whole genome gene expression profiles of HepaRG cells and HepG2 cells to primary human hepatocytes and human liver tissues.

Drug Metab. Dispos. 38:988-994(2010)

PubMed=20645056; DOI=10.1007/978-1-60761-688-7_13

Marion M.-J., Hantz O., Durantel D.

The HepaRG cell line: biological properties and relevance as a tool for cell biology, drug metabolism, and virology studies.

Methods Mol. Biol. 640:261-272(2010)

PubMed=21414303; DOI=10.1016/j.bcp.2011.03.004

Ceelen L., De Spiegelaere W., David M., De Craene J., Vinken M., Vanhaecke T., Rogiers V.

Critical selection of reliable reference genes for gene expression study in the HepaRG cell line.

Biochem. Pharmacol. 81:1255-1261(2011)

PubMed=22568886; DOI=10.1517/17425255.2012.685159

Andersson T.B., Kanebratt K.P., Kenna J.G.

The HepaRG cell line: a unique in vitro tool for understanding drug metabolism and toxicology in human.

Expert Opin. Drug Metab. Toxicol. 8:909-920(2012)

PubMed=22594799; DOI=10.3109/13813455.2012.683442

Samanez C.H., Caron S., Briand O., Dehondt H., Duplan I., Kuipers F., Hennuyer N., Clavey V., Staels B.

The human hepatocyte cell lines IHH and HepaRG: models to study glucose, lipid and lipoprotein metabolism.

Arch. Physiol. Biochem. 118:102-111(2012)

PubMed=22643240; DOI=10.1016/j.tiv.2012.05.008

Antherieu S., Chesne C., Li R., Guguen-Guillouzo C., Guillouzo A.

Optimization of the HepaRG cell model for drug metabolism and toxicity studies.

Toxicol. In Vitro 26:1278-1285(2012)

PubMed=22857383; DOI=10.1186/1477-5956-10-47

Sokolowska I., Dorobantu C., Woods A.G., Macovei A., Branza-Nichita N., Darie C.C.

Proteomic analysis of plasma membranes isolated from undifferentiated and differentiated HepaRG cells.

Proteome Sci. 10:47-47(2012)

PubMed=23887712; DOI=10.1038/ncomms3218

Nault J.-C., Mallet M., Pilati C., Calderaro J., Bioulac-Sage P., Laurent C., Laurent A., Cherqui D., Balabaud C., Zucman-Rossi J.

High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions.

Nat. Commun. 4:2218-2218(2013)

PubMed=26160117; DOI=10.1093/toxsciv136

Sison-Young R.L.C., Mitsa D., Jenkins R.E., Mottram D., Alexandre E., Richert L., Aerts H., Weaver R.J., Jones R.P., Johann E., Hewitt P.G., Ingelman-Sundberg M., Goldring C.E.P., Kitteringham N.R., Park B.K.

Comparative proteomic characterization of 4 human liver-derived single cell culture models reveals significant variation in the capacity for drug disposition, bioactivation, and detoxication.

Toxicol. Sci. 147:412-424(2015)

PubMed=26694163; DOI=10.1371/journal.pone.0144924

Janiszewska J., Szaumkessel M., Kostrzewska-Poczekaj M., Bednarek K., Paczkowska J., Jackowska J., Grenman R., Szyfter K., Wierzbicka M., Giefing M., Jarmuz-Szymczak M.

Global miRNA expression profiling identifies miR-1290 as novel potential oncomiR in laryngeal carcinoma.

PLoS ONE 10:E0144924-E0144924(2015)

PubMed=27169750; DOI=10.1038ep24709

Sharanek A., Burban A., Burbank M., Le Guevel R., Li R., Guillouzo A., Guguen-Guillouzo C.

Rho-kinase/myosin light chain kinase pathway plays a key role in the impairment of bile canaliculi dynamics induced by cholestatic drugs.

Sci. Rep. 6:24709-24709(2016)

PubMed=27780834; DOI=10.1124/dmd.116.072603

van der Mark V.A., de Waart D.R., Shevchenko V., Oude Elferink R.P.J., Chamuleau R.A.F.M., Hoekstra R.

Stable overexpression of the constitutive androstane receptor reduces the requirement for culture with dimethyl sulfoxide for high drug metabolism in HepaRG cells.

Drug Metab. Dispos. 45:56-67(2017)

PubMed=27975304; DOI=10.1007/978-1-4939-6700-1_2

Ni Y., Urban S.

Hepatitis B virus infection of HepaRG cells, HepaRG-hNTCP cells, and primary human hepatocytes.

Methods Mol. Biol. 1540:15-25(2017)

PubMed=28904299; DOI=10.2131/jts.42.641

Tomida T., Ishimura M., Iwaki M.

A cell-based assay using HepaRG cells for predicting drug-induced phospholipidosis.

J. Toxicol. Sci. 42:641-650(2017)